

## Livtencity (maribavir) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID NUN	/IBER:			
IF YOU ARE NOT THE PATIENT OR THE PRESCRI FOLLOWING LINK: <u>HTTPS://MAGELLANRX.COM</u>	BER, YOU WILL NEED TO SUBMIT A PHI DISCLO	SURE AUTHORIZATION FORM WITH THIS REQUENT/DOC/EN-US/PHI DISCLOSURE AUTHORIZA	JEST WHICH CAN BE FOUND AT THE TION.PDF	
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):				
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL I	DISPENSING INFORMATION			
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
NEW THERAPY RENEWAL IF RENEWAL: DATE THERAPY INITIATED:		INITIATED:		
DURATION OF THERAPY (SPE	CIFIC DATES):			

Continued on next page.





## Livtencity (maribavir) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR		
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
☐ Cytomegaloviral disease (CMV)				
□ Other diagnosis:	ICD-10:			
	PLEASE PROVIDE ALL RELEVANT CLINICA	AL INFORMATION TO SUPPORT A		
PRIOR AUTHORIZATION.	ingle trial 2 - Vec - No			
Is this drug being used as part of a clin	ical trial?   Yes   No			
Has the patient had a solid organ trans	splant or allogenic hematopoietic stem	cell transplantation?   Yes   No		
		·		
Does the member have a documented cytomegalovirus (CMV) infection in whole blood or plasma (i.e., screening				
	≥ 910 IU/mL in plasma) in 2 consecutive	e assessments separated by ≥ 1 day?		
☐ Yes ☐ No Please provide lab docur	mentation and dates.			
Does the member have current CMV in	nfection that is refractory to at least 2 a	nti-CMV treatment agents (e.g		
	r foscarnet)?   Yes   No Provide doc			
Will maribavir be coadministered with ganciclovir or valganciclovir be avoided? ☐ Yes ☐ No				
For <u>renewal</u> , additionally answer the fo	ollowing:			
Tor <u>renewar</u> , additionally answer the i	onowing.			
Does the patient have disease improve	ement and/or stabilization OR improver	nent in the slope of decline?		
$\ \square$ Yes $\ \square$ No $\ \ $ Documentation and lab	values must be provided.			
Does the provider attest that the patie	ent is NOT resistant (or a non-responder	) to maribavir?   Yes   No		
Are there any other comments, diagno	oses, symptoms, medications tried or fai	iled, and/or any other information the		
physician feels is important to this rev		nea, and, or any other information the		
<u> </u>	e covered on all plans. This request may	be denied unless all required		
information is received.				
	provided is true and accurate to the bes	· -		
	or its designees may perform a routine	·		
information necessary to verify the acc	uracy of the information reported on thi	s torm.		
Prescriber Signature or Flectronic L.D.	Verification:	Date:		





## Livtencity (maribavir) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

**FAX THIS FORM TO: 800-424-7640** 

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



